Navigation Links
Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load
Date:3/17/2008

ter of this year."

About RDEA806

RDEA806 is a novel non-nucleoside reverse transcriptase inhibitor (NNRTI) for the potential treatment of HIV infection. Based on preclinical and clinical studies to-date, Ardea believes that RDEA806 may have important competitive advantages. These include the potential for potent antiviral activity against a wide range of HIV viral isolates, including those that are resistant to efavirenz (SUSTIVA(R)) and other currently available NNRTIs; a high genetic barrier to resistance; the potential to be administered in a patient-friendly, oral dosing regimen; limited pharmacokinetic interactions with other drugs; and the ability to be co-formulated with other HIV antiviral drugs.

Conference Call Details

To participate in tomorrow's live call by telephone, please dial 877-440-5786 from the U.S. or +1-719-325-4862 for international callers. In addition, the live conference call is being webcast and can be accessed on the "News & Events" page of the Company's website at http://www.ardeabio.com. A replay will also be available on Ardea's website and by telephone for 14 days following the live presentation. In the U.S., please dial 888-203-1112 or +1-719-457-0820 for international callers and, when prompted, enter passcode 8779421.

About Ardea Biosciences, Inc.

Ardea Biosciences, of San Diego, California, is a biotechnology company focused on the discovery and development of small-molecule therapeutics for the treatment of HIV, cancer and inflammatory diseases, including gout. The Company has two product candidates in clinical development and several others in preclinical development. Ardea's most advanced clinical development candidate is RDEA806, a non-nucleoside reverse transcriptase inhibitor (NNRTI), which is in a Phase 2a study for the treatment of HIV. In addition, the Company is investigating RDEA806 for the treatment of gout. The Company's lead
'/>"/>

SOURCE Ardea Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus
2. Ardea Biosciences, Inc. Announces New Clinical Development Program Directed Toward the Treatment of Gout
3. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
4. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
5. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
6. Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results
7. Neurocrine Biosciences Reports Fourth Quarter and Year-End 2007 Results
8. CeloNova BioSciences Introduces a New Class of Coronary Stent: The CATANIA(TM) Coronary Stent System with NanoThin Polyzene(R)-F
9. CeloNova BioSciences Announces Positive Results from European Study of Embozene(TM) Microspheres for Treatment of Uterine Fibroids
10. Epiphany Biosciences Reports Initiation of Phase 2 Study of Valomaciclovir for the Treatment of Acute Infectious Mononucleosis
11. Sangamo BioSciences Announces Completion of Enrollment of Phase 2 Clinical Trial of ZFP Therapeutic for Diabetic Neuropathy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... 2014   BioNano Genomics announced today achievement of ... collect human data at 30X depth, sufficient for a genome ... capability was established and demonstrated for the IrysChip TM ... System and will be rolled out to BioNano,s collaborators ... showcasing this advancement at the American Society for Human ...
(Date:10/20/2014)... 2014 Pharmaceutic Labs announces the opening of ... Albany, NY for admixing, compounding, drug shortages ... exceeds the FDA standards for safety and quality, using ... The 10,000 square foot outsourcing facility ... assurance and quality control. The company will produce sterile ...
(Date:10/19/2014)... 20, 2014 Shire plc (LSE: SHP, NASDAQ: ... Chief Financial Officer (CFO), has notified the Board of Directors of ... a new career opportunity as CFO of Severn Trent plc.  James ... company will commence a search for a new CFO immediately. ... has helped build and lead a high-quality finance team at Shire. ...
Breaking Medicine Technology:BioNano Genomics Announces One Human : One Chip : One Day 2BioNano Genomics Announces One Human : One Chip : One Day 3Interim Chief Financial Officer James Bowling to Step Down 2Interim Chief Financial Officer James Bowling to Step Down 3Interim Chief Financial Officer James Bowling to Step Down 4
... ANTONIO, Oct. 6 Nautilus Neurosciences, Inc., ... Pharmacal Company, a privately-held pharmaceutical company focused ... their exclusive co-promotion agreement for CAMBIA™ (diclofenac ... and other women,s health medical professionals. CAMBIA™ ...
... Gerresheimer Reports Strong Earnings and Sales Growth -- DUSSELDORF, Germany, October 6, 2010 ... ... --> ... s = ,; var first_result; // Results are keyed by longUrl, so we need to grab the ...
Cached Medicine Technology:Nautilus Neurosciences and Mission Pharmacal Announce Exclusive Co-Promotion Agreement for CAMBIA™ (diclofenac potassium for oral solution) for the Acute Treatment of Migraine to the Women's Health Market 2Nautilus Neurosciences and Mission Pharmacal Announce Exclusive Co-Promotion Agreement for CAMBIA™ (diclofenac potassium for oral solution) for the Acute Treatment of Migraine to the Women's Health Market 3Nautilus Neurosciences and Mission Pharmacal Announce Exclusive Co-Promotion Agreement for CAMBIA™ (diclofenac potassium for oral solution) for the Acute Treatment of Migraine to the Women's Health Market 4Gerresheimer Reports Strong Earnings and Sales Growth 2Gerresheimer Reports Strong Earnings and Sales Growth 3Gerresheimer Reports Strong Earnings and Sales Growth 4Gerresheimer Reports Strong Earnings and Sales Growth 5Gerresheimer Reports Strong Earnings and Sales Growth 6Gerresheimer Reports Strong Earnings and Sales Growth 7Gerresheimer Reports Strong Earnings and Sales Growth 8Gerresheimer Reports Strong Earnings and Sales Growth 9
(Date:10/20/2014)... NY (PRWEB) October 20, 2014 ... non-profit organization that helps New Yorkers living with ... changes toward health, housing, recovery and self-sufficiency. Each ... transformed the local community through their tireless efforts. ... Marc Shapses , has been selected as ...
(Date:10/20/2014)... JZ Fitness, an independently operated wellness ... programming, authorship, international lecturing and community wellness, created by ... release of the JZ Fitness nutrition app, available on ... thousands of individuals on nutrition, Jenn Zerling (“JZ”) has ... require calorie counting or cumbersome food logging. ...
(Date:10/20/2014)... 2014 Rockynol Retirement Community ... Oct. 14. The $11 million project will include the ... cooked-to-order kitchen with full-service restaurant style dining. , “We ... first class Assisted Living apartments,” said Kara Hanzie, Rockynol ... highest quality of care and this investment is proof ...
(Date:10/20/2014)... Unveiled at the Sept. 18 board meeting, The Center for ... ROI on membership dues at 12.5. In other words, for ... value to member hospitals. The calculation used to determine member ... , “This is the first time we’ve actually been able ... is really sound,” said Bill Ryan , president and ...
(Date:10/19/2014)... 2014 Hastings and Hastings, a Phoenix ... service throughout the greater Phoenix area and across Arizona ... regard to catastrophic automobile accidents. Statistics have indicated a ... throughout Arizona. As such, Hastings and Hastings has seen ... for those who have been injured through no fault ...
Breaking Medicine News(10 mins):Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 2Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 3Health News:JZ Fitness Nutrition App Launches on iTunes 2Health News:JZ Fitness Nutrition App Launches on iTunes 3Health News:Rockynol Retirement Community Expands Assisted Living Center 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 3Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 4Health News:Hastings And Hastings Reports Record Demand In 2014 For Legal Representation With Regard To Catastrophic Automobile Accidents 2Health News:Hastings And Hastings Reports Record Demand In 2014 For Legal Representation With Regard To Catastrophic Automobile Accidents 3
... WASHINGTON, July 7 Cardinal Justin Rigali, Chairman of ... today to final guidelines for human embryonic stem cell ... (NIH). The text of his statement follows: , ... for destructive embryonic stem cell research, saying that under ...
... heart drugs get the wrong dose or end up on ... children, according to research led by the Johns Hopkins Children,s ... While the researchers found the highest number of ... children of all ages are vulnerable to such mistakes because ...
... -- Chemical dependency and recovery in patients and physicians ... editorials in the July 2009 issue of Mayo ... the immense challenges, including potential tragedies, of prescription chemical ... crucial overview, direction and optimism. Addiction to ...
... DVA ), a leading provider of kidney ... (CKD), today opened its 100th DaVita Academy - the ... new teammates (employees). On hand to participate and ... former United States Senator Paul Sarbanes and Congressman Elijah ...
... 7 DRINKiQ.com , Diageo,s cutting edge ... as the Most Outstanding Health and Wellness web site by ... was also named runner-up in the Education Category. Now ... excellence for communications professionals. The program is sanctioned by the ...
... Bonnie Yanelli ... ... a leading quality improvement and care management organization, named Bonnie Yanelli and Joseph Krolak as ... to increase KePRO,s market share and the company,s overall revenue. , , , , ...
Cached Medicine News:Health News:Cardinal Rigali Criticizes Final NIH Guidelines for Destructive Stem Cell Research 2Health News:Wrong dose of heart meds too frequent in children 2Health News:A comprehensive review of addiction to prescription painkillers among patients and physicians 2Health News:A comprehensive review of addiction to prescription painkillers among patients and physicians 3Health News:DaVita's Award-Winning Training Program for New Teammates Reaches Milestone With 100th DaVita Academy in Baltimore, Maryland 2Health News:Diageo's DRINKiQ.com Honored as Most Outstanding Health & Wellness Site by International Academy of the Visual Arts 2Health News:Diageo's DRINKiQ.com Honored as Most Outstanding Health & Wellness Site by International Academy of the Visual Arts 3Health News:KePRO Names Two New Business Development Directors 2
... surface preparation is the Leica SM2500 sledge ... ,Ultramilling is often a viable alternative to ... preparation. Especially with difficult specimens, where hard ... side in one specimen block, the results ...
... The Trellis Infusion Catheter enables the physician ... physician-specified fluid, and disperse the agent by ... The Trellis is a multi-lumen catheter with ... end and infusion holes located between these ...
... The SENSAR® Acrylic IOL with OptiEdge ... performance, long-term refractive stability, and excellent handling. ... has had no reports of vacuoles; the ... internal reflections and provide 360 degrees of ...
... acrylic foldable single-piece posterior chamber lenses are ... human crystalline lens in the visual correction ... age and older. The optical portion consists ... material. These lenses have biconvex optics and ...
Medicine Products: